Los Angeles – September 13, 2026 -- Hyper3D has launched WorldGen, a world-generation model that converts a single image into a 3D scene made up of independent, editable objects, extending the company's generative 3D technology beyond single-object creation into full scene reconstruction for robotics, filmmaking and game development.
Cambridge, Mass. – September 13, 2026 -- Solstice Oncology has launched with a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors, to advance a second-generation CTLA-4 antibody into earlier-stage cancer treatment.
The clinical-stage company is focused on treating cancer in the neoadjuvant setting, before tumors have hardened resistance to therapy. Its lead candidate, porustobart, is a differentiated, Fc-enhanced CTLA-4 antibody being developed across two clinical indications, including microsatellite-stable (MSS) colon cancer and a second, undisclosed indication.
Lufkin – September 13, 2026 -- Lemon Seed Marketing will host its seventh annual Lemon Seed Conference, themed "Into the Wilderness," on March 3-6, 2027, at Timber Creek Church's Lufkin, Texas campus.
The conference targets home service business owners and leaders, offering sessions on finance and operations, leadership and team building, and community engagement alongside a vendor expo. Crystal Williams, co-owner and lead strategist at Lemon Seed, said the "wilderness" theme reflects how independent home service owners navigate a competitive marketing landscape.
Los Angeles – September 13, 2026 -- Partillion Bioscience has secured a two-year, $2.1 million NIH Small Business Innovation Research (SBIR) award from the National Institute of General Medical Sciences (NIGMS), pushing the company's total non-dilutive federal funding past $8 million.
The award, Partillion's 10th SBIR grant, was competitively secured through NIH's Direct-to-Phase II mechanism and roughly matches the company's private investment total, with no additional equity exchanged. The funding, awarded under grant number R44GM165220, will support development of the company's Cell-Cell-seq workflows over two years.
Whites Creek, Tennessee – September 13, 2026 -- Brennan Investment Group has commenced construction on a 210,000 square-foot, Class A speculative industrial facility on 17 acres in Whites Creek, Tennessee, with completion targeted for the second quarter of 2027.
The property is located less than a half-mile from the Interstate 24 interchange at Old Hickory Boulevard, giving future occupiers access to Nashville's three major interstates. Andrew Mazey, Brennan's Senior Vice President for the Nashville and Atlanta regions, said the location will draw last-mile and regional distribution users, and sits a 30-minute drive from Clarksville, Tennessee, a fast-growing manufacturing market.
Singapore – September 13, 2026 -- SuperX AI Technology Limited (NASDAQ: SUPX) repurchased 119,360 ordinary shares on September 8, 2026, at an average net price of US$7.7691 per share, a transaction valued at roughly US$927,000.
SuperX's Board of Directors approved the 2026 Repurchase Program on August 6, 2026, granting management authority to repurchase up to US$20 million of ordinary shares over the following twelve months. The company stated the move reflects Board and management confidence that current market valuation does not fully capture the firm's intrinsic value and long-term growth potential.
New York – September 13, 2026 -- Eddid Securities USA Inc., a FINRA-registered introducing broker-dealer, has secured FINRA-approved correspondent clearing arrangements with tZERO Group under FINRA Rule 4311, granting its clients regulated access to digital asset securities trading and custody.
Eddid USA, the U.S. subsidiary of Hong Kong-based Eddid Financial, has entered agreements with tZERO's regulated broker-dealer subsidiaries covering trading, clearing, and custody. As a subscriber to the tZERO Securities ATS, operated by tZERO Securities, LLC, Eddid USA can now facilitate customer trading in eligible securities, including digital asset securities.
Toronto – September 13, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) will hold a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 10:30 a.m. EDT.
The session takes place in the Louis Room on the fourth floor of the venue. A live webcast will be available under the Events & Presentations section of the company's investor website.
Cardiol's lead candidate, CardiolRx, is being evaluated in the pivotal Phase III MAVERIC trial (NCT06708299) for recurrent pericarditis, following the completed Phase II MAvERIC-Pilot study (NCT05494788). The U.S. FDA has granted Orphan Drug Designation to CardiolRx for pericarditis, including the recurrent form of the disease.
Sydney – September 13, 2026 -- Kazia Therapeutics Limited (NASDAQ: KZIA) has dosed the first patient in Arm A of PNOC035, a Phase 2 platform study testing paxalisib combined with gemcitabine for recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT), an aggressive pediatric brain cancer with no approved therapies.
In an orthotopic AT/RT preclinical model, the paxalisib-gemcitabine combination extended median survival from 22 to 82.5 days (p0.0001) and showed complementary anti-tumor activity across multiple AT/RT cell lines. These findings, previously presented at ISPNO, AACR and Neuro-Oncology meetings, formed the scientific basis for advancing into the multicenter PNOC035 trial.
New York – – September 12, 2026 -- Brand Engagement Network, Inc. (NASDAQ: BNAI) and Cataneo GmbH will present an AI-enhanced version of the MYDAS advertising platform at IBC2026, targeting broadcasters and media companies still running on legacy on-premises systems.
Cataneo's cloud-native MYDAS platform manages advertising sales, scheduling, traffic, content management, monetization, analytics, CRM integration, and real-time reporting across more than 1,000 media brands and over 200 broadcast and digital channels worldwide, including major U.S. film studios.